Share-based Payment Arrangement, Expense of Amylyx Pharmaceuticals, Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Amylyx Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • Amylyx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,076,000, a 4% increase year-over-year.
  • Amylyx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $28,000,000, a 22% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $33,038,000, a 11% decline from 2023.
  • Amylyx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $37,161,000, a 71% increase from 2022.
  • Amylyx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21,714,000, a 592% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Amylyx Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $28,000,000 $7,076,000 +$273,000 +4% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $27,727,000 $7,350,000 -$2,220,000 -23% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $29,947,000 $6,833,000 -$3,091,000 -31% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $33,038,000 $6,741,000 -$2,793,000 -29% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $35,831,000 $6,803,000 -$3,373,000 -33% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $39,204,000 $9,570,000 -$380,000 -3.8% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $39,584,000 $9,924,000 +$2,423,000 +32% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $37,161,000 $9,534,000 +$3,443,000 +57% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $33,718,000 $10,176,000 +$4,652,000 +84% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $29,066,000 $9,950,000 +$4,243,000 +74% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $24,823,000 $7,501,000 +$3,109,000 +71% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $21,714,000 $6,091,000 +$5,000,000 +458% 01 Oct 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $16,714,000 $5,524,000 +$4,722,000 +589% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $11,992,000 $5,707,000 +$5,050,000 +769% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,942,000 $4,392,000 +$3,806,000 +649% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $3,136,000 $1,091,000 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $802,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $657,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $586,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

Amylyx Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $33,038,000 -$4,123,000 -11% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $37,161,000 +$15,447,000 +71% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $21,714,000 +$18,578,000 +592% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $3,136,000 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.